In this regard, we found that human lymphoma cells that either contain TRAF3 loss (Ly-7) or have TRAF3 deleted (Ly-1-TRAF3-KO) were more sensitive to IAP antagonist treatment than their TRAF3 WT controls. Here, TRAF3 is linked to lymphoma.